Predictive value of 3′-deoxy-3′-(18)F-fluorothymidine PET in the early response to anti-programmed death-1 therapy in patients with advanced non-small cell lung cancer

BACKGROUND: Anti-programmed death-1 (anti-PD-1) therapy has shown clinical success in patients with advanced non-small cell lung cancer (NSCLC). However, it is difficult to evaluate the early response to anti-PD-1 therapy. We determined whether changes in 3′-deoxy-3′-[(18)F]-fluorothymidine ((18)F-F...

Descripción completa

Detalles Bibliográficos
Autores principales: Sato, Masayuki, Umeda, Yukihiro, Tsujikawa, Tetsuya, Mori, Tetsuya, Morikawa, Miwa, Anzai, Masaki, Waseda, Yuko, Kadowaki, Maiko, Kiyono, Yasushi, Okazawa, Hidehiko, Ishizuka, Tamotsu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2021
Materias:
Immunotherapy Biomarkers
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8296775/
https://www.ncbi.nlm.nih.gov/pubmed/34301816
http://dx.doi.org/10.1136/jitc-2021-003079

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8296775/
https://www.ncbi.nlm.nih.gov/pubmed/34301816
http://dx.doi.org/10.1136/jitc-2021-003079

Ejemplares similares